

# **Cardiac Marker Testing Market by Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Product (Instrument (Chemiluminescence, ELISA), Reagents & Kits), Disease (MI, CHF, Atherosclerosis), User, ASP & Buying Criteria - Global Forecast to 2028**

<https://marketpublishers.com/r/C4C53F41C88EN.html>

Date: October 2023

Pages: 216

Price: US\$ 4,950.00 (Single User License)

ID: C4C53F41C88EN

## **Abstracts**

The global cardiac marker testing market is projected to reach USD 6.9 billion by 2028 from USD 4.1 billion in 2022, growing at a CAGR of 9.4% during the forecast period. The projected surge in market growth for cardiac marker testing is underpinned by a confluence of compelling advantages. Notably, cardiac marker testing is driven by aging population, rising cases of cardiovascular diseases, increase in research & funding initiatives from public/private organizations to discover novel cardiac biomarkers. Furthermore, the escalating early detection of heart failure diseases with improved efficacy for diagnosing heart conditions amplifies the demand for advanced treatment modalities, with cardiac marker testing positioned as a forefront solution. This convergence of factors is poised to usher in a phase of robust expansion within the market, consequently shaping the landscape of cardiac marker testing adoption in the forthcoming forecasting years.

“Troponin I and T segment to register largest market share in 2022-2028”

Based on the biomarker type, cardiac marker testing market is segmented into Troponin I and T, Creatine Kinase-MB (CK-MB), Brain Natriuretic Peptide (BNP and NT-PROBNP), Myoglobin, High-sensitivity C-reactive Protein (hs-CRP), and other cardiac biomarkers. The Troponin I and T segment register a largest market share over the forecast period of 2022-2028. The growth of this segment is propelled by factors such as exceptional sensitivity and specificity, prolonged elevation duration (with levels rising over 4-8 hours, peaking at 10-24 hours, and declining over ten days), and the swift

prediction of outcomes. Moreover, lab technicians are more adept at utilizing these markers in comparison to other biomarkers, further fueling the segment's advancement.

“Laboratory testing facilities segment held the largest share of cardiac marker testing market in 2022, by End-user.”

Based on the end-user, the cardiac marker testing market is segmented into laboratory testing facilities, academic institutes, and point-of-care testing facilities. In 2022, the laboratory testing facilities segment accounted for the largest share of 61.2% of the global cardiac marker testing market. The growth of this segment is being propelled by factors including increased testing efficiency, superior sensitivity and diagnostic precision in comparison to point-of-care testing, and a strong preference for laboratory testing over point-of-care testing.

“Asia Pacific to register significant growth rate in the market during the forecast period.”

For the forecasting period 2023-2028, the APAC region is expected to register a significant growth rate in the market during the forecast period. Asia Pacific comprises India, China, Japan, Australia, South Korea, and RoAPAC. The Asia-Pacific (APAC) region has witnessed a significant increase in the market growth rate for cardiac marker testing. There are several drivers that contributed to this growth:

The Asia Pacific market is experiencing growth due to increased investments by government agencies in emerging countries, aimed at enhancing healthcare infrastructure. Additionally, the market is benefiting from the rise in independent clinical laboratories, a substantial patient population, and strategic initiatives by industry players to expand their offerings of cardiac testing products in the Asia Pacific region.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1–43%, Tier 2–30%, and Tier 3– 27%

By Designation: C-level–10%, Director-level–15%, and Others–75%

By Region: North America–40%, Europe–30%, Asia Pacific–23%, Latin America–5%, and the Middle East & Africa–2%

Prominent players in this market are F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), , Thermo Fisher Scientific Inc. (US) among others.

## Research Coverage

The report studies the marker testing market based on products, biomarker type, diseases, end user, and region.

The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.

The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.

The report studies micro markets with respect to their growth trends, prospects, and contributions to the global cardiac marker testing market

The report forecasts the revenue of market segments with respect to five major regions.

## Key Benefits of Buying the Report:

The report will help the new entrants/ market leaders/smaller firms in this market with investment evaluation viability within the cardiac marker testing market through a thorough analysis of comprehensive data, thereby facilitating robust risk assessment and enabling well-informed investment determinations. Benefit from meticulous market segmentation encompassing application, end-user, and regional dimensions, affording tailored insights for precise segment targeting. The report also provides an all-encompassing evaluation of encapsulating pivotal trends, challenges, growth catalysts and prospects, thereby empowering strategic decision-making with astute discernment.

The report provides insights on the following pointers:

Analysis of key drivers (increasing prevalence of cardiovascular diseases, Increasing geriatric population and subsequent rise in heart conditions worldwide, Ongoing clinical trials for the identification of novel cardiac

biomarkers), restraints (Technical issues related to sample collection & storage, Unfavorable regulatory processes and limited reimbursement structure), opportunities (Point-of-care testing (POCT) with cardiac biomarkers, Emerging markets offers high-growth opportunities, Ongoing research on novel cardiac biomarkers for cardiovascular diseases), and challenges (Challenges associated with biomarker assay validation) influencing the growth of the cardiac marker testing market

**Product Development/Innovation:** Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the cardiac marker testing market.

**Market Development:** Comprehensive information about lucrative markets – the report analyses the cardiac marker testing market across varied regions.

**Market Diversification:** Exhaustive information about new products, untapped geographies, recent developments, and investments in the cardiac marker testing market

**Competitive Assessment:** In-depth assessment of market shares, growth strategies, and service offerings of leading players like F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), among others.

## Contents

### 1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
  - 1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
- 1.3 MARKET SCOPE
  - 1.3.1 MARKETS COVERED
  - 1.3.2 REGIONS COVERED
- 1.4 YEARS CONSIDERED
- 1.5 CURRENCY
- 1.6 RESEARCH LIMITATIONS
- 1.7 MARKET STAKEHOLDERS
- 1.8 SUMMARY OF CHANGES
  - 1.8.1 RECESSION IMPACT

### 2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
- 2.2 RESEARCH DESIGN
  - 2.2.1 SECONDARY RESEARCH
    - FIGURE 1 KEY DATA FROM SECONDARY SOURCES
  - 2.2.2 PRIMARY RESEARCH
    - 2.2.2.1 Primary sources
    - 2.2.2.2 Key industry insights
    - 2.2.2.3 Breakdown of primaries
- FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
- FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
- 2.3 MARKET SIZE ESTIMATION
  - FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    - 2.3.1 BOTTOM-UP APPROACH
      - 2.3.2 APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH
        - FIGURE 5 CARDIAC MARKER TESTING MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)
      - 2.3.3 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION
        - FIGURE 6 CARDIAC MARKER TESTING MARKET SIZE ESTIMATION: BOTTOM-UP

## APPROACH

### 2.3.4 APPROACH 3: TOP-DOWN APPROACH

### 2.3.5 APPROACH 4: PRIMARY INTERVIEWS

## FIGURE 7 CARDIAC MARKER TESTING MARKET SIZE ESTIMATION: TOP-DOWN APPROACH

## 2.4 DATA TRIANGULATION AND MARKET BREAKDOWN

### FIGURE 8 DATA TRIANGULATION METHODOLOGY

## 2.5 MARKET SHARE ASSESSMENT

## 2.6 STUDY ASSUMPTIONS

## 2.7 RISK ASSESSMENT

### TABLE 1 LIMITATIONS AND ASSOCIATED RISKS

## 2.8 GROWTH RATE ASSUMPTIONS

## 2.9 RECESSION IMPACT

## 3 EXECUTIVE SUMMARY

FIGURE 9 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2023 VS. 2028 (USD MILLION)

FIGURE 10 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)

FIGURE 11 CARDIAC MARKER TESTING MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)

FIGURE 12 CARDIAC MARKER TESTING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)

FIGURE 13 GEOGRAPHICAL SNAPSHOT OF CARDIAC MARKER TESTING MARKET

## 4 PREMIUM INSIGHTS

### 4.1 CARDIAC MARKER TESTING MARKET OVERVIEW

FIGURE 14 RISING PREVALENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET

4.2 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY AND END USER, 2022

FIGURE 15 LABORATORY TESTING FACILITIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022

### 4.3 CARDIAC MARKER TESTING MARKET: REGIONAL MIX

FIGURE 16 NORTH AMERICA WILL CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD

#### 4.4 CARDIAC MARKER TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

### 5 MARKET OVERVIEW

#### 5.1 INTRODUCTION

FIGURE 18 CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

##### 5.1.1 DRIVERS

5.1.1.1 Rising prevalence of cardiovascular diseases

5.1.1.2 Increasing geriatric population and subsequent rise in heart conditions worldwide

5.1.1.3 Growing research and funding initiatives from public and private organizations

5.1.1.4 Rising clinical studies for identification of novel cardiac biomarkers

##### 5.1.2 RESTRAINTS

5.1.2.1 Technical issues related to sample collection and storage

5.1.2.2 Unfavorable regulatory processes and limited reimbursement structure

##### 5.1.3 OPPORTUNITIES

5.1.3.1 Point-of-care testing with cardiac biomarkers

5.1.3.2 Ongoing research on novel cardiac biomarkers for cardiovascular diseases

5.1.3.3 Emerging markets

##### 5.1.4 CHALLENGES

5.1.4.1 Challenges associated with biomarker assay validation

#### 5.2 KEY STAKEHOLDERS AND BUYING CRITERIA

##### 5.2.1 KEY STAKEHOLDERS IN BUYING PROCESS

FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CARDIAC MARKER TESTING MARKET

TABLE 2 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY PRODUCT SEGMENTS (%)

#### 5.3 PORTER'S FIVE FORCES ANALYSIS

TABLE 3 CARDIAC MARKER TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS

5.3.1 THREAT OF NEW ENTRANTS

5.3.2 THREAT OF SUBSTITUTES

5.3.3 BARGAINING POWER OF SUPPLIERS

5.3.4 BARGAINING POWER OF BUYERS

5.3.5 INTENSITY OF COMPETITIVE RIVALRY

## 5.4 REGULATORY ANALYSIS

### 5.4.1 US

#### TABLE 4 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS

### 5.4.2 EUROPE

#### TABLE 5 EUROPE: CLASSIFICATION OF IVD DEVICES

### 5.4.3 JAPAN

#### TABLE 6 JAPAN: CLASSIFICATION OF IVD REAGENTS

#### TABLE 7 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS

## 5.5 REIMBURSEMENT SCENARIO

#### TABLE 8 REIMBURSEMENT CODES FOR VARIOUS BIOMARKERS

## 5.6 ECOSYSTEM MAPPING

## 5.7 VALUE CHAIN ANALYSIS

### 5.7.1 RESEARCH & DEVELOPMENT

### 5.7.2 PROCUREMENT AND PRODUCT DEVELOPMENT

### 5.7.3 MARKETING, SALES AND DISTRIBUTION, AND POST-SALES SERVICES

#### FIGURE 20 VALUE CHAIN ANALYSIS OF CARDIAC MARKER TESTING MARKET

## 5.8 SUPPLY CHAIN ANALYSIS

### 5.8.1 PROMINENT COMPANIES

### 5.8.2 SMALL & MEDIUM-SIZED COMPANIES

### 5.8.3 END USERS

#### FIGURE 21 SUPPLY CHAIN ANALYSIS OF CARDIAC MARKER TESTING MARKET

## 5.9 PRICING ANALYSIS

#### TABLE 9 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER TROPONIN I AND T TEST KITS, 2021

#### TABLE 10 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER BPN AND NT-PROBNP TEST KITS, 2021

#### TABLE 11 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER MYOGLOBIN TEST KITS, 2021

#### TABLE 12 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER CK-MB TEST KITS, 2022

#### TABLE 13 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER C-REACTIVE PROTEIN (HS-CRP) TEST KITS, 2022

#### TABLE 14 AVERAGE SELLING PRICE TREND OF CARDIAC MARKER TEST KITS, BY COUNTRY, 2021–2023 (USD)

## 5.10 PATENT ANALYSIS

#### FIGURE 22 TOP 10 PATENT APPLICANTS FOR CARDIAC MARKER TESTING, JANUARY 2012–SEPTEMBER 2022

#### FIGURE 23 TOP 10 PATENT OWNERS FOR CARDIAC MARKER TESTING, JANUARY 2012–SEPTEMBER 2022

## 5.11 TRADE ANALYSIS

TABLE 15 IMPORT DATA FOR CARDIAC MARKER TESTING (HS CODE 3822), BY COUNTRY, 2018–2022 (USD THOUSAND)

TABLE 16 EXPORT DATA FOR CARDIAC MARKER TESTING (HS CODE 3822), BY COUNTRY, 2018–2022 (USD THOUSAND)

## 5.12 CASE STUDIES

TABLE 17 CASE STUDY: BREAKTHROUGH IN ACUTE MYOCARDIAL INFARCTION DIAGNOSIS WITH HIGH-SENSITIVITY TROPONIN I ASSAYS

## 5.13 KEY CONFERENCES AND EVENTS, 2023–2024

TABLE 18 CARDIAC MARKER TESTING MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS IN 2023–2024

## 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS

FIGURE 24 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX

## 5.15 IMPACT OF RECESSION ON CARDIAC MARKER TESTING MARKET

# 6 CARDIAC MARKER TESTING MARKET, BY PRODUCT

## 6.1 INTRODUCTION

TABLE 19 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

## 6.2 REAGENTS & KITS

### 6.2.1 RISING VOLUME OF DIAGNOSTIC TESTS TO DRIVE DEMAND

TABLE 20 CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION)

TABLE 21 CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)

## 6.3 INSTRUMENTS

TABLE 22 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)

TABLE 23 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION)

TABLE 24 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)

### 6.3.1 CHEMILUMINESCENCE

#### 6.3.1.1 Most preferred method for quantifying cardiac biomarkers

TABLE 25 CHEMILUMINESCENCE INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION)

TABLE 26 CHEMILUMINESCENCE INSTRUMENTS MARKET, BY REGION,

2021–2028 (USD MILLION)

### 6.3.2 IMMUNOFLUORESCENCE

6.3.2.1 Demand for stable and safer reagents to support market growth

TABLE 27 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION)

TABLE 28 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)

### 6.3.3 ELISA

6.3.3.1 Long shelf life and ease of use to propel growth

TABLE 29 ELISA INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION)

TABLE 30 ELISA INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)

### 6.3.4 IMMUNOCHROMATOGRAPHY

6.3.4.1 Increasing use in point-of-care settings to propel adoption

TABLE 31 IMMUNOCHROMATOGRAPHY INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION)

TABLE 32 IMMUNOCHROMATOGRAPHY INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)

## 7 CARDIAC MARKER TESTING MARKET, BY INDICATION

### 7.1 INTRODUCTION

TABLE 33 CARDIAC MARKER TESTING MARKET, BY INDICATION, 2021–2028 (USD MILLION)

### 7.2 MYOCARDIAL INFARCTION

7.2.1 AVAILABILITY OF HIGH-SENSITIVITY BIOMARKERS FOR DETECTION TO DRIVE MARKET

TABLE 34 CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2021–2028 (USD MILLION)

### 7.3 CONGESTIVE HEART FAILURE

7.3.1 INCREASING USE OF MULTIMARKER TESTING TO SUPPORT MARKET GROWTH

TABLE 35 CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2021–2028 (USD MILLION)

### 7.4 ACUTE CORONARY SYNDROME

7.4.1 INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE ADOPTION OF CARDIAC MARKERS

TABLE 36 CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2021–2028 (USD MILLION)

## 7.5 ATHEROSCLEROSIS

### 7.5.1 HIGH PREVALENCE OF ATHEROSCLEROSIS TO DRIVE MARKET

TABLE 37 CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2021–2028 (USD MILLION)

## 7.6 ISCHEMIA

### 7.6.1 INCREASE IN CARDIAC ISCHEMIA TO BOOST DEMAND FOR CARDIAC MARKER TESTS

TABLE 38 CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY REGION, 2021–2028 (USD MILLION)

## 8 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE

### 8.1 INTRODUCTION

TABLE 39 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION)

### 8.2 TROPONIN I AND T

#### 8.2.1 HIGH SENSITIVITY AND SPECIFICITY IN DETECTION OF CVD TO DRIVE MARKET

TABLE 40 TROPONIN I AND T CARDIAC MARKER TESTING MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 41 TROPONIN I AND T CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 42 TROPONIN I AND T CARDIAC MARKER TESTING MARKET, BY REGION, 2021–2028 (USD MILLION)

### 8.3 CREATINE KINASE-MB

#### 8.3.1 POOR SPECIFICITY AND BRIEF ELEVATION DURATION TO HAMPER MARKET GROWTH

TABLE 43 CREATINE KINASE-MB CARDIAC MARKER TESTING MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 44 CREATINE KINASE-MB CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 45 CREATINE KINASE-MB CARDIAC MARKER TESTING MARKET, BY REGION, 2021–2028 (USD MILLION)

### 8.4 BRAIN NATRIURETIC PEPTIDE

#### 8.4.1 USE OF BNP WITH OTHER CARDIAC MARKERS TO ENHANCE UTILIZATION

TABLE 46 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY INDICATION, 2021–2028 (USD MILLION)

TABLE 47 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY END USER, 2021–2028 (USD MILLION)

TABLE 48 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY REGION, 2021–2028 (USD MILLION)

#### 8.5 MYOGLOBIN

8.5.1 USED TO ASSESS PATIENTS WITH CHEST PAIN IN EMERGENCY DEPARTMENT SETTINGS

TABLE 49 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 50 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY END USER, 2021–2028 (USD MILLION)

TABLE 51 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY REGION, 2021–2028 (USD MILLION)

#### 8.6 HIGH-SENSITIVITY C-REACTIVE PROTEIN

8.6.1 INCREASING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL ADOPTION

TABLE 52 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 53 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY END USER, 2021–2028 (USD MILLION)

TABLE 54 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY REGION, 2021–2028 (USD MILLION)

#### 8.7 OTHER CARDIAC BIOMARKERS

TABLE 55 OTHER CARDIAC BIOMARKERS MARKET, BY INDICATION, 2021–2028 (USD MILLION)

TABLE 56 OTHER CARDIAC BIOMARKERS MARKET, BY END USER, 2021–2028 (USD MILLION)

TABLE 57 OTHER CARDIAC BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION)

## 9 CARDIAC MARKER TESTING MARKET, BY END USER

### 9.1 INTRODUCTION

TABLE 58 CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)

### 9.2 LABORATORY TESTING FACILITIES

TABLE 59 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2021–2028 (USD MILLION)

TABLE 60 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY REGION, 2021–2028 (USD MILLION)

#### 9.2.1 HOSPITAL LABORATORIES

9.2.1.1 Early diagnosis associated with in-house labs to support market growth  
TABLE 61 CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION)

#### 9.2.2 REFERENCE LABORATORIES

9.2.2.1 Affordable and time-efficient services associated with reference laboratories to drive market

TABLE 62 CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2021–2028 (USD MILLION)

#### 9.2.3 CONTRACT TESTING LABORATORIES

9.2.3.1 Ability to perform multiple tests to propel market  
TABLE 63 CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2021–2028 (USD MILLION)

### 9.3 ACADEMIC INSTITUTES

9.3.1 CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET

TABLE 64 CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021–2028 (USD MILLION)

### 9.4 POINT-OF-CARE TESTING FACILITIES

9.4.1 EARLY DETECTION AND LOWER TURNAROUND TIME TO PROPEL MARKET

TABLE 65 CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING FACILITIES, BY REGION, 2021–2028 (USD MILLION)

## 10 CARDIAC MARKER TESTING MARKET, BY REGION

### 10.1 INTRODUCTION

TABLE 66 CARDIAC MARKER TESTING MARKET, BY REGION, 2021–2028 (USD MILLION)

### 10.2 NORTH AMERICA

#### 10.2.1 NORTH AMERICA: RECESSION IMPACT

FIGURE 25 NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT

TABLE 67 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 68 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 69 NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)

TABLE 70 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION)

TABLE 71 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)

10.2.2 US

10.2.2.1 Growing support from NIH for development of novel cardiac biomarkers to drive market

TABLE 72 US: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

10.2.3 CANADA

10.2.3.1 Government initiatives to support market growth

TABLE 73 CANADA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

10.3 EUROPE

10.3.1 EUROPE: RECESSION IMPACT

TABLE 74 EUROPE: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 75 EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 76 EUROPE: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)

TABLE 77 EUROPE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION)

TABLE 78 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)

10.3.2 GERMANY

10.3.2.1 Favorable government policies to support market growth

TABLE 79 GERMANY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

10.3.3 FRANCE

10.3.3.1 Rising geriatric population to drive market

TABLE 80 FRANCE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

10.3.4 UK

10.3.4.1 Government initiatives to boost adoption of cardiac biomarkers

TABLE 81 UK: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

10.3.5 ITALY

10.3.5.1 Adoption of advanced diagnostic technologies to drive market

TABLE 82 ITALY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

### 10.3.6 SPAIN

10.3.6.1 Establishment of large and advanced laboratories to drive uptake of cardiac marker testing

TABLE 83 SPAIN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

### 10.3.7 REST OF EUROPE

TABLE 84 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

## 10.4 ASIA PACIFIC

### 10.4.1 ASIA PACIFIC: RECESSION IMPACT

FIGURE 26 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT

TABLE 85 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 86 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 87 ASIA PACIFIC: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)

TABLE 88 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION)

TABLE 89 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)

### 10.4.2 JAPAN

10.4.2.1 Presence of advanced laboratory facilities to drive market

TABLE 90 JAPAN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

### 10.4.3 CHINA

10.4.3.1 Growing number of independent clinical laboratories to drive demand for cardiac markers

TABLE 91 CHINA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

### 10.4.4 INDIA

10.4.4.1 Presence of large patient population to drive demand

TABLE 92 INDIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

### 10.4.5 AUSTRALIA

10.4.5.1 Increasing healthcare expenditure to support market growth

TABLE 93 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

### 10.4.6 SOUTH KOREA

10.4.6.1 Growing number of private hospitals to drive adoption of advanced testing services

TABLE 94 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

10.4.7 REST OF ASIA PACIFIC

TABLE 95 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

10.5 LATIN AMERICA

10.5.1 LATIN AMERICA: RECESSION IMPACT

TABLE 96 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 97 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 98 LATIN AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)

TABLE 99 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION)

TABLE 100 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)

10.5.2 BRAZIL

10.5.2.1 Increasing government support for advancements in healthcare to support market growth

TABLE 101 BRAZIL: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

10.5.3 MEXICO

10.5.3.1 Rising demand for technologically advanced products to drive uptake of cardiac markers

TABLE 102 MEXICO: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

10.5.4 REST OF LATIN AMERICA

TABLE 103 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

10.6 MIDDLE EAST & AFRICA

10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE DEMAND FOR ADVANCED MARKERS

10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

TABLE 104 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 105 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING INSTRUMENTS

MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)

TABLE 106 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION)

TABLE 107 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION)

10.6.3 GCC COUNTRIES

## **11 COMPETITIVE LANDSCAPE**

11.1 OVERVIEW

11.2 STRATEGIES ADOPTED BY KEY PLAYERS

11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CARDIAC MARKER TESTING MARKET

11.3 REVENUE SHARE ANALYSIS

FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET, 2018–2022 (USD MILLION)

11.4 MARKET RANKING ANALYSIS

11.5 COMPANY EVALUATION MATRIX

11.5.1 STARS

11.5.2 EMERGING LEADERS

11.5.3 PERVASIVE PLAYERS

11.5.4 PARTICIPANTS

FIGURE 29 CARDIAC MARKER TESTING MARKET: COMPANY EVALUATION MATRIX, 2022

11.6 STARTUP/SME EVALUATION MATRIX

11.6.1 PROGRESSIVE COMPANIES

11.6.2 STARTING BLOCKS

11.6.3 RESPONSIVE COMPANIES

11.6.4 DYNAMIC COMPANIES

FIGURE 30 CARDIAC MARKER TESTING MARKET: STARTUP/SME EVALUATION MATRIX, 2022

11.7 COMPANY FOOTPRINT

TABLE 108 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET

TABLE 109 PRODUCT FOOTPRINT ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET

TABLE 110 REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET

11.8 COMPETITIVE SCENARIOS AND TRENDS

TABLE 111 KEY PRODUCT LAUNCHES

TABLE 112 KEY DEALS

TABLE 113 OTHER KEY DEVELOPMENTS

## **12 COMPANY PROFILES**

### **12.1 KEY PLAYERS**

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))\*

#### **12.1.1 F. HOFFMANN-LA ROCHE AG**

TABLE 114 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW

FIGURE 31 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2022)

#### **12.1.2 ABBOTT LABORATORIES**

TABLE 115 ABBOTT LABORATORIES: COMPANY OVERVIEW

FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)

#### **12.1.3 SIEMENS HEALTHINEERS AG**

TABLE 116 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW

FIGURE 33 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)

#### **12.1.4 DANAHER CORPORATION**

TABLE 117 DANAHER CORPORATION: COMPANY OVERVIEW

FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)

#### **12.1.5 BIO-RAD LABORATORIES, INC.**

TABLE 118 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW

FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)

#### **12.1.6 BIOM?RIEUX SA**

TABLE 119 BIOM?RIEUX SA: COMPANY OVERVIEW

FIGURE 36 BIOM?RIEUX SA: COMPANY SNAPSHOT (2022)

#### **12.1.7 BECTON, DICKINSON AND COMPANY**

TABLE 120 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW

FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)

#### **12.1.8 THERMO FISHER SCIENTIFIC INC.**

TABLE 121 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW

FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)

#### **12.1.9 DIASORIN S.P.A.**

TABLE 122 DIASORIN S.P.A.: COMPANY OVERVIEW

FIGURE 39 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)

#### **12.1.10 PERKINELMER INC.**

TABLE 123 PERKINELMER INC.: COMPANY OVERVIEW

FIGURE 40 PERKINELMER INC.: COMPANY SNAPSHOT (2022)

12.1.11 TOSOH CORPORATION

TABLE 124 TOSOH CORPORATION: COMPANY OVERVIEW

FIGURE 41 TOSOH CORPORATION: COMPANY SNAPSHOT (2023)

12.1.12 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION)

TABLE 125 LSI MEDIENCE CORPORATION: COMPANY OVERVIEW

FIGURE 42 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)

12.1.13 QUIDEL CORPORATION

TABLE 126 QUIDEL CORPORATION: COMPANY OVERVIEW

FIGURE 43 QUIDEL CORPORATION: COMPANY SNAPSHOT (2022)

12.1.14 RANDOX LABORATORIES

TABLE 127 RANDOX LABORATORIES: COMPANY OVERVIEW

12.1.15 GUANGZHOU WONDFO BIOTECH CO., LTD.

TABLE 128 GUANGZHOU WONDFO BIOTECH CO., LTD.: BUSINESS OVERVIEW

12.1.16 BODITECH MED INC.

TABLE 129 BODITECH MED INC.: BUSINESS OVERVIEW

12.1.17 TULIP DIAGNOSTICS (P) LTD.

TABLE 130 TULIP DIAGNOSTICS (P) LTD.: BUSINESS OVERVIEW

12.1.18 BTNX INC.

TABLE 131 BTNX INC.: BUSINESS OVERVIEW

12.1.19 RESPONSE BIOMEDICAL

TABLE 132 RESPONSE BIOMEDICAL: BUSINESS OVERVIEW

12.1.20 ALFA SCIENTIFIC DESIGNS, INC.

TABLE 133 ALFA SCIENTIFIC DESIGNS, INC.: BUSINESS OVERVIEW

12.2 OTHER PLAYERS

12.2.1 CTK BIOTECH, INC.

12.2.2 CREATIVE DIAGNOSTICS

12.2.3 LIFESIGN LLC

12.2.4 CARDIOGENICS HOLDINGS INC.

12.2.5 ATLAS MEDICAL GMBH

\*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

## 13 APPENDIX

13.1 DISCUSSION GUIDE

13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL

13.3 CUSTOMIZATION OPTIONS

13.4 RELATED REPORTS

13.5 AUTHOR DETAILS

## I would like to order

Product name: Cardiac Marker Testing Market by Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Product (Instrument (Chemiluminescence, ELISA), Reagents & Kits), Disease (MI, CHF, Atherosclerosis), User, ASP & Buying Criteria - Global Forecast to 2028

Product link: <https://marketpublishers.com/r/C4C53F41C88EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C4C53F41C88EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970